
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative functional genes and briefly note what they indicate.<br><br>**Cytotoxic / effector program**<br>- **NKG7, GZMK, GZMA, GZMB, GZMH**: Canonical cytotoxic granule components and granzymes; hallmark of cytotoxic lymphocytes (CD8 T cells and NK cells).  <br>- **CCL5**: Chemokine highly expressed in activated cytotoxic T cells and NK cells.  <br>- **IFNG**: Signature Th1 / cytotoxic effector cytokine.  <br>- **CXCL13**: Chemokine associated with T follicular helper‚Äìlike and ‚Äúperipheral helper‚Äù T cells, but also seen in chronically activated/exhausted CD8 T cells in tumors and inflamed tissues.  <br>- **SIT1**: T cell activation‚Äìassociated transmembrane protein, enriched in cytotoxic T/NK populations.  <br>- **CXCR4**: Chemokine receptor; broadly expressed in T cells, often upregulated in activated/trafficking T cells.<br><br>**T cell receptor and core T cell program**<br>- **CD3D, CD3E, CD3G, CD2**: Core T cell receptor complex and pan‚ÄìT cell markers.  <br>- **TRAC, TRBC1**: TCR Œ± and Œ≤ constant regions; definitive TCR+ T cells.  <br>- **CD8A, CD8B**: CD8 co-receptor; hallmark of CD8+ T cells (cytotoxic T lymphocytes).  <br>- **CTLA4**: Immune checkpoint receptor; induced upon activation, often in chronically stimulated or regulatory/exhausted T cells.  <br>- **BCL11B**: T-lineage‚Äìdefining transcription factor; required for T cell identity.  <br>- **GFI1**: Transcription factor involved in T cell and NK cell differentiation and effector programming.<br><br>**Cell cycle / proliferation / chromatin**<br>- **MKI67, ASPM, NUSAP1, E2F8, MXD3, FAM111B, NEIL3**: Strong proliferative/cell cycle signature (MKI67+ ASPM+ NUSAP1+ is classic cycling T cell profile).  <br>- **HIST1H2AJ, HIST1H2AL, HIST1H3B, HIST1H2AH, HIST1H2AI, HIST1H1B, HIST1H2BF, HIST1H2AK, HIST1H3G, HIST1H4C, HIST1H1D, HMGB2**: Histones and chromatin-associated proteins; typically upregulated in S/G2/M phases and in highly proliferative cells.<br><br>**Innate/cytotoxic receptor**<br>- **KIR2DL4**: Killer-cell immunoglobulin-like receptor; classically associated with NK cells and some cytotoxic T cells (especially tissue-resident or chronically stimulated CD8 T cells that acquire NK-like features).<br><br>**Other / less informative in this context**<br>- **APOBEC3H**: Antiviral restriction factor; often expressed in lymphocytes.  <br>- **FXYD2**: Na/K-ATPase modulator; not a canonical T cell marker, may be low-level or context-specific expression.  <br>- **LINC02539, AC007240.1, AC243829.4, LINC00158**: lncRNAs; not standard lineage markers but may be activation/proliferation associated.<br><br>2. Key cell type markers (tissue/cell identity)<br><br>From the list, the clear lineage-defining markers are:<br><br>**T cell lineage**<br>- **CD3D/E/G, CD2, TRAC, TRBC1, BCL11B**: Unambiguous T cell identity.  <br>- **CD8A, CD8B**: CD8+ T cell subset.  <br>- **CTLA4, CXCR4, CCL5, IFNG, GZMs, NKG7**: Activated effector T cells, particularly cytotoxic CD8 T cells.<br><br>**NK vs T distinction**<br>- NK cells: typically **NKG7, GZMB, GZMH, CCL5, KIR2DL4** are strong, but NK cells lack **CD3/TCR**.  <br>- Here, **strong CD3/TCR (CD3D/E/G, TRAC, TRBC1) and BCL11B** clearly indicate **T cells**, not NK cells, though they share a cytotoxic program and one KIR.<br><br>**Brain tissue context**<br>- No neuronal (e.g., SNAP25, RBFOX3), astrocytic (GFAP, AQP4), oligodendroglial (MBP, PLP1), microglial (CX3CR1, P2RY12, TMEM119), or endothelial/pericyte markers are present.  <br>- This is a classic **infiltrating immune (T cell) cluster** in brain tissue (e.g., tumor, MS, or other neuroinflammatory context).<br><br>3. Cross-referencing with scRNA-seq databases / literature<br><br>Comparisons to known references:<br><br>- **Human brain immune infiltrates (glioma, MS, neuroinflammation)**:  <br>  - Studies such as Neftel et al. Cell 2019 (glioblastoma), and multiple MS lesion atlases, show **CD8+ cytotoxic T cell clusters** with high **CD3D/E, CD8A/B, NKG7, GZMB, GZMK, CCL5, IFNG**, often with **MKI67+ proliferative subsets**.  <br>- **T cell atlases (e.g., Azimuth PBMC, Human Cell Atlas, ImmGen-like resources)**:  <br>  - ‚Äú**CD8 effector / cytotoxic T cells**‚Äù and ‚Äú**CD8 effector memory T cells**‚Äù express **CD3D/E, CD8A/B, NKG7, GZMB, GZMH, GZMK, CCL5, IFNG, CXCR4**.  <br>  - ‚Äú**Cycling CD8 T cells**‚Äù add **MKI67, ASPM, NUSAP1, E2F8, HIST1H2* genes**.  <br>- **Exhausted/chronically activated CD8 T cells in tumors**:  <br>  - Often show **GZMK, CXCL13, CTLA4**, sometimes KIR expression, with a cytotoxic background. CXCL13+ CD8 T cells are a well-described intratumoral subset.<br><br>The combination of **CD3+CD8+ cytotoxic markers + strong proliferation + CXCL13/CTLA4** is highly consistent with **activated, proliferating cytotoxic CD8 T cells**, likely in an inflamed or tumor microenvironment.<br><br>4. Most probable general cell type<br><br>- **General lineage**: T lymphocyte (T cell).  <br>- **CD8 vs CD4**: Strong **CD8A/B** and absence of CD4/Th markers ‚Üí **CD8+ T cell**.  <br>- **Functional state**: Cytotoxic, activated, and proliferating.<br><br>**Most probable general cell type: CD8+ cytotoxic T lymphocytes (T cells).**<br><br>5. Top 3 most probable sub cell types (ranked)<br><br>Within CD8 T cells, the markers point to specific functional/phenotypic states.<br><br>### 1) Most likely: Proliferating cytotoxic CD8+ effector T cells (Ki-67+ cycling CD8 T cells)<br><br>**Supporting markers:**<br>- **Cytotoxic effector program**: NKG7, GZMB, GZMH, GZMK, GZMA, CCL5, IFNG.  <br>- **T cell identity**: CD3D/E/G, CD2, TRAC, TRBC1, BCL11B.  <br>- **CD8 lineage**: CD8A, CD8B.  <br>- **Proliferation/cell cycle**: MKI67, ASPM, NUSAP1, E2F8, MXD3, NEIL3, FAM111B, HMGB2, multiple HIST1H* genes.  <br>- **Activation/exhaustion**: CTLA4, CXCL13, CXCR4, GFI1.<br><br>This is the classic signature of **cycling effector CD8 T cells** seen in inflamed tissues and tumors: high cytotoxic genes plus a strong S/G2/M program. The presence of **CXCL13 and CTLA4** suggests chronic activation, but the dominant feature is **proliferation + cytotoxicity**.<br><br>**Annotation for #1:**  <br>**‚ÄúProliferating cytotoxic CD8+ effector T cells (Ki-67+ CD8 T cells)‚Äù**<br><br>---<br><br>### 2) Second most likely: Activated/exhausted cytotoxic CD8+ T cells (tumor- or inflammation-associated, CXCL13+)<br><br>If one emphasizes the **CXCL13 and CTLA4** expression, this aligns with:<br><br>- **CXCL13+ CD8 T cells** described in tumors and chronic inflammation, often considered **exhausted or peripheral helper‚Äìlike CD8 T cells** that recruit B cells and organize tertiary lymphoid structures.  <br>- **CTLA4** and possibly KIR2DL4 suggest chronic stimulation and acquisition of NK-like features.<br><br>These cells are still **CD8+ cytotoxic T cells**, but with a more **exhausted/chronically activated phenotype** rather than purely effector.<br><br>**Annotation for #2:**  <br>**‚ÄúActivated/exhausted CXCL13+ cytotoxic CD8+ T cells (tumor-/inflammation-associated CD8 T cells)‚Äù**<br><br>---<br><br>### 3) Third most likely: NK-like CD8+ T cells (CD8 T cells with NK receptor acquisition)<br><br>The presence of **KIR2DL4** alongside a strong cytotoxic program raises the possibility of:<br><br>- **NK-like CD8 T cells** (sometimes called ‚Äúinnate-like‚Äù or ‚Äúadaptive NK-like‚Äù CD8 T cells), which express KIRs and share features with NK cells but retain TCR/CD3 expression.  <br>- These are often tissue-resident or chronically stimulated CD8 T cells in inflamed tissues.<br><br>However, the **dominant TCR/CD3 signature and proliferation markers** make this a secondary interpretation.<br><br>**Annotation for #3:**  <br>**‚ÄúNK-like cytotoxic CD8+ T cells (KIR2DL4+ CD8 T cells)‚Äù**<br><br>---<br><br>**Most likely subtype (final choice):**  <br>Given the very strong **MKI67/ASPM/NUSAP1/HIST1H* proliferation signature** together with a robust cytotoxic CD8 program, the most parsimonious and data-driven annotation is:<br><br>> **Proliferating cytotoxic CD8+ effector T cells (Ki-67+ CD8 T cells)**<br><br>6. Concise summary<br><br>- The cluster expresses **canonical T cell markers (CD3D/E/G, TRAC, TRBC1, CD2, BCL11B)** and **CD8A/B**, clearly identifying it as **CD8+ T cells**.  <br>- High levels of **NKG7, GZMB, GZMH, GZMK, GZMA, CCL5, IFNG** define a **cytotoxic effector program**.  <br>- A strong **cell cycle/proliferation signature** (MKI67, ASPM, NUSAP1, E2F8, multiple histones) indicates these are **actively cycling**.  <br>- **CTLA4, CXCL13, CXCR4, KIR2DL4** suggest chronic activation and some NK-like/exhausted features, consistent with **brain-infiltrating T cells** in an inflammatory or tumor context.  <br><br>**Final annotation:**  <br>- **General cell type:** CD8+ cytotoxic T lymphocytes  <br>- **Most likely subtype:** **Proliferating cytotoxic CD8+ effector T cells (Ki-67+ CD8 T cells)**<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">CD8+ cytotoxic T lymphocytes</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Proliferating cytotoxic CD8+ effector T cells (Ki-67+ CD8 T cells)</li><li>Activated/exhausted CXCL13+ cytotoxic CD8+ T cells (tumor-/inflammation-associated CD8 T cells)</li><li>NK-like cytotoxic CD8+ T cells (KIR2DL4+ CD8 T cells)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cytotoxic CD8+ T cells with NK-like features (due to KIR2DL4 expression)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    